本文選題：腎腫瘤 + 腎細(xì)胞癌　； 參考：《第二軍醫(yī)大學(xué)學(xué)報(bào)》2016年07期

【摘要】：目的探討RNA干擾p38基因?qū)θ四I癌細(xì)胞株786-O增殖、侵襲、細(xì)胞周期和細(xì)胞對舒尼替尼敏感性的影響。方法構(gòu)建針對p38的siRNA531和siRNA659兩條siRNA,分別將其轉(zhuǎn)染至腎癌786-O細(xì)胞株,即為siRNA531組和siRNA659組,同時(shí)設(shè)置轉(zhuǎn)染無義siRNA的陰性對照組和僅加轉(zhuǎn)染試劑的空白對照組。應(yīng)用RT-PCR技術(shù)檢測786-O細(xì)胞p38mRNA的表達(dá),蛋白質(zhì)印跡法檢測p38蛋白的表達(dá)。CCK-8法檢測細(xì)胞的增殖情況和對舒尼替尼的敏感性,流式細(xì)胞術(shù)檢測細(xì)胞的周期改變情況,Transwell實(shí)驗(yàn)檢測細(xì)胞的侵襲能力。結(jié)果 RT-PCR及蛋白質(zhì)印跡法檢測發(fā)現(xiàn)siRNA轉(zhuǎn)染后786-O細(xì)胞p38mRNA及蛋白的表達(dá)均降低。與空白對照組和陰性對照組相比,siRNA531組和siRNA659組786-O細(xì)胞在轉(zhuǎn)染后3~5d時(shí)的增殖率均降低(P0.05,P0.01),細(xì)胞對舒尼替尼的敏感性增加,兩組對舒尼替尼的IC50值均低于陰性對照組[(3.2±0.3)、(1.4±0.1)μmol/mL vs(5.4±0.2)μmol/mL,P0.05]。siRNA531組、siRNA659組G1期細(xì)胞數(shù)量明顯多于對照組,且兩組786-O細(xì)胞出現(xiàn)G0/G1阻滯。轉(zhuǎn)染24h后,兩組的穿膜細(xì)胞數(shù)分別為56.43±6.02、34.00±8.12,與陰性對照組(76.27±5.08)相比,兩組細(xì)胞的侵襲能力均下降(P0.01)。結(jié)論通過轉(zhuǎn)染p38特異性siRNA可以成功沉默腎癌細(xì)胞株786-O的p38基因的表達(dá),抑制腎癌細(xì)胞株786-O的增殖、侵襲能力,增加其對舒尼替尼的敏感性,為后續(xù)研究腎癌治療及靶向耐藥奠定基礎(chǔ)。
[Abstract]:Objective to investigate the effects of RNA interference p38 gene on proliferation, invasion, cell cycle and cell sensitivity of human renal cell carcinoma cell line 786-O. Methods two siRNAs targeting p38 siRNA531 and siRNA659 were constructed and transfected into 786-O cell line of renal cell carcinoma, that is, siRNA531 group and siRNA659 group respectively. The negative control group transfected with nonsense siRNA and the blank control group with only transfection reagent were set up at the same time. The expression of p38mRNA in 786-O cells was detected by RT-PCR, the expression of p38 protein by Western blotting and the proliferation and sensitivity to sunitinib by CCK-8 assay. Cell cycle changes were detected by flow cytometry and the invasion ability was detected by Transwell assay. Results RT-PCR and Western blot analysis showed that the expression of p38mRNA and protein in 786-O cells decreased after siRNA transfection. Compared with the blank control group and the negative control group, the proliferation rate of 786-O cells in the siRNA531 group and the siRNA659 group decreased at 3 and 5 days after transfection, and the sensitivity of the cells to sulnitinib was increased. The IC50 value of sunitinib in both groups was significantly lower than that in negative control group [3.2 鹵0.3 鹵0.3 渭 mol/mL vs(5.4 鹵0.2 渭 mol 路mL 路mL] .siRNA531 group had significantly higher cell number in G1 phase than that in control group, and 786-O cells were blocked by G0/G1 in both groups. 24 hours after transfection, the number of transmembrane cells in the two groups was 56.43 鹵6.02 鹵34.00 鹵8.12, respectively, which was significantly lower than that in the negative control group (76.27 鹵5.08). Conclusion transfection of p38 specific siRNA can successfully silence the expression of p38 gene in 786-O cell line, inhibit the proliferation and invasion of 786-O cell line, and increase its sensitivity to sunitinib. To lay a foundation for further study of renal cell carcinoma treatment and targeted drug resistance.
【作者單位】： 第二軍醫(yī)大學(xué)長征醫(yī)院泌尿外科;武警河南總隊(duì)醫(yī)院泌尿外科;解放軍458醫(yī)院泌尿外科;第二軍醫(yī)大學(xué)長海醫(yī)院泌尿外科;南京大學(xué)醫(yī)學(xué)院附屬金陵醫(yī)院南京軍區(qū)南京總醫(yī)院泌尿外科;
【基金】：國家自然科學(xué)基金(81272817,81172447) 上海市自然科學(xué)基金(11ZR1447800)~~
【分類號(hào)】：R737.11

【相似文獻(xiàn)】

相關(guān)期刊論文 前10條

1 吳晶;秦叔逵;;舒尼替尼治療轉(zhuǎn)移性腎細(xì)胞癌的臨床藥物經(jīng)濟(jì)學(xué)研究進(jìn)展[J];臨床腫瘤學(xué)雜志;2009年09期

2 曾彥;秦叔逵;;舒尼替尼治療中國晚期腎細(xì)胞癌患者新進(jìn)展[J];中國處方藥;2010年12期

3 王忠堯;康新立;;單核苷酸多態(tài)性與舒尼替尼一線治療進(jìn)展期腎細(xì)胞癌患者的療效、不良反應(yīng)的相關(guān)性分析:一個(gè)多中心、觀察、前瞻性研究(譯文)[J];藥品評價(jià);2012年30期

4 張亮;陳立軍;趙立;王亞林;李建濤;唐飛;黃晨;曲楠;麥海星;李學(xué)超;;生血寶合劑治療蘋果酸舒尼替尼骨髓抑制的療效觀察[J];軍事醫(yī)學(xué);2013年04期

5 姜小良;尹志康;譚兵;吳小候;;藤黃酸聯(lián)合舒尼替尼抑制腎癌細(xì)胞的增殖[J];第三軍醫(yī)大學(xué)學(xué)報(bào);2014年07期

6 劉京;趙正焱;;舒尼替尼對轉(zhuǎn)移性腎腫瘤的安全性和效果觀察[J];中國醫(yī)藥指南;2011年09期

7 鮮鵬;羅宏;周宏;李元;戴君勇;王傳麟;;舒尼替尼對腎透明細(xì)胞癌不同轉(zhuǎn)移灶療效的探討[J];臨床泌尿外科雜志;2011年05期

8 郭剛;張帆;明少雄;張旭;;舒尼替尼治療晚期腎細(xì)胞癌存活期超過3年病例分析:單中心11例報(bào)告[J];臨床泌尿外科雜志;2014年03期

9 郭剛;張帆;杜青山;馮丹;張旭;;舒尼替尼在晚期腎細(xì)胞癌二線序貫治療中的臨床應(yīng)用研究[J];臨床泌尿外科雜志;2014年01期

10 黃宏星;;歐盟批準(zhǔn)舒尼替尼在晚期腎細(xì)胞癌一線用藥的全市場準(zhǔn)入[J];中國醫(yī)藥導(dǎo)刊;2007年01期

相關(guān)會(huì)議論文 前5條

1 陳貴平;李方印;王華;王宗平;邱彭年;劉卓;宋正波;;舒尼替尼治療晚期轉(zhuǎn)移性腎癌22例報(bào)告[A];2012浙江省醫(yī)學(xué)會(huì)男科學(xué)、泌尿外科學(xué)術(shù)年會(huì)論文匯編[C];2012年

2 吳晶;張楠;董鵬;;舒尼替尼一線治療中國轉(zhuǎn)移性腎細(xì)胞癌患者的藥物經(jīng)濟(jì)學(xué)評價(jià)[A];2011年中國藥學(xué)大會(huì)暨第11屆中國藥師周論文集[C];2011年

3 胡驍軼;王國民;郭劍明;林宗明;孫立安;許明;徐志兵;王杭;戎瑞明;倉晨;;舒尼替尼治療晚期腎癌中血液學(xué)不良反應(yīng)的診治體會(huì)[A];華東六省一市泌尿外科學(xué)術(shù)年會(huì)暨2011年浙江省泌尿外科、男科學(xué)學(xué)術(shù)年會(huì)論文匯編[C];2011年

4 于楠;吳翔;李學(xué)松;高瑩;何志嵩;郭曉蕙;;29例應(yīng)用舒尼替尼治療腎細(xì)胞癌患者的甲狀腺功能觀察及分析[A];中華醫(yī)學(xué)會(huì)第十次全國內(nèi)分泌學(xué)學(xué)術(shù)會(huì)議論文匯編[C];2011年

5 胡R，

本文編號(hào)：1853969